John Porter, DO
Internal Medicine · Montgomery, ALNPI 1205182508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 351 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$682
- Amarin Pharma, Inc.$603
- Novo Nordisk$543
- Pfizer$373
- Astellas Pharma US Inc$326
- plus $2K from 21 others
Across 1,041 payments — averaging $297.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$294K
- AstraZeneca$8K
- Chiesi USA, Inc.$4K
- Boehringer Ingelheim$4K
What the payments were for
- Food & beverage$5,74598%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 78 | $1,169 |
| AstraZeneca | 30 | $682 |
| Amarin Pharma, Inc. | 39 | $603 |
| Novo Nordisk | 32 | $543 |
| Pfizer | 23 | $373 |
| Astellas Pharma US Inc | 16 | $326 |
| Lilly USA, LLC | 23 | $302 |
| Boehringer Ingelheim | 12 | $199 |
| AbbVie(2 entities) | 9 | $198 |
| Amgen(2 entities) | 11 | $197 |
| Johnson & Johnson(2 entities) | 11 | $175 |
| Sanofi-aventis U.S. LLC | 10 | $157 |
| Sumitomo Pharma America, Inc. | 8 | $150 |
| Exact Sciences | 7 | $120 |
| Bayer | 6 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $100 |
| Novartis | 7 | $99 |
| Kowa Pharmaceuticals America, Inc. | 7 | $91 |
| Sunovion Pharmaceuticals Inc. | 6 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Merck | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Bioventus LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
How this compares
$5,839 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 236 | $221,077 |
| JanuviaSitagliptin Phosphate | 198 | $183,109 |
| OzempicSemaglutide | 118 | $139,153 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $133,843 |
| JardianceEmpagliflozin | 106 | $128,138 |
| TrulicityDulaglutide | 71 | $90,965 |
| VascepaIcosapent Ethyl | 165 | $84,294 |
| EliquisApixaban | 84 | $78,612 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $64,287 |
| RybelsusSemaglutide | 38 | $49,015 |
| LinzessLinaclotide | 55 | $48,242 |
| XareltoRivaroxaban | 48 | $47,100 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $42,279 |
| MyrbetriqMirabegron | 46 | $40,011 |
| MounjaroTirzepatide | 36 | $38,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $682 | $270,009300 claims |
| MerckJanuvia, Janumet Xr, Janumet | $17 | $222,183246 claims |
| Novo NordiskOzempic, Rybelsus | $543 | $188,168156 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $199 | $181,563172 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,169 | $169,450200 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $302 | $129,958107 claims |
| PfizerEliquis | $373 | $78,61284 claims |
| AbbVieLinzess | $198 | $48,24255 claims |
| Johnson & JohnsonXarelto | $175 | $47,10048 claims |
| Astellas Pharma US IncMyrbetriq | $326 | $40,01146 claims |
| NovartisEntresto | $99 | $36,19040 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $150 | $36,03533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Montgomery
- Joel McCloudMontgomery$27K
- John JerniganMontgomery$25K
- Norman TaylorMontgomery$16K
- Ashok RunkanaMontgomery$14K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.